BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 25609071)

  • 21. HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation.
    Carroll JB; Deik A; Fossale E; Weston RM; Guide JR; Arjomand J; Kwak S; Clish CB; MacDonald ME
    PLoS One; 2015; 10(8):e0134465. PubMed ID: 26295712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
    Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
    Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease.
    Ferrari Bardile C; Garcia-Miralles M; Caron NS; Rayan NA; Langley SR; Harmston N; Rondelli AM; Teo RTY; Waltl S; Anderson LM; Bae HG; Jung S; Williams A; Prabhakar S; Petretto E; Hayden MR; Pouladi MA
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9622-9627. PubMed ID: 31015293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease.
    Carroll JB; Lerch JP; Franciosi S; Spreeuw A; Bissada N; Henkelman RM; Hayden MR
    Neurobiol Dis; 2011 Jul; 43(1):257-65. PubMed ID: 21458571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insights into White Matter Defect in Huntington's Disease.
    Sun Y; Tong H; Yang T; Liu L; Li XJ; Li S
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deficiency of Ube3a in Huntington's disease mice brain increases aggregate load and accelerates disease pathology.
    Maheshwari M; Shekhar S; Singh BK; Jamal I; Vatsa N; Kumar V; Sharma A; Jana NR
    Hum Mol Genet; 2014 Dec; 23(23):6235-45. PubMed ID: 25027318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease.
    Canals JM; Pineda JR; Torres-Peraza JF; Bosch M; Martín-Ibañez R; Muñoz MT; Mengod G; Ernfors P; Alberch J
    J Neurosci; 2004 Sep; 24(35):7727-39. PubMed ID: 15342740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD.
    Rattray I; Smith E; Gale R; Matsumoto K; Bates GP; Modo M
    PLoS One; 2013; 8(4):e60012. PubMed ID: 23593159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Downregulation of p75
    Suelves N; Miguez A; López-Benito S; Barriga GG; Giralt A; Alvarez-Periel E; Arévalo JC; Alberch J; Ginés S; Brito V
    Mol Neurobiol; 2019 Feb; 56(2):935-953. PubMed ID: 29804232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
    Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
    Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease.
    Pineda JR; Canals JM; Bosch M; Adell A; Mengod G; Artigas F; Ernfors P; Alberch J
    J Neurochem; 2005 Jun; 93(5):1057-68. PubMed ID: 15934928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease.
    Smith GA; Rocha EM; McLean JR; Hayes MA; Izen SC; Isacson O; Hallett PJ
    Hum Mol Genet; 2014 Sep; 23(17):4510-27. PubMed ID: 24728190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.
    Wu B; Jiang M; Peng Q; Li G; Hou Z; Milne GL; Mori S; Alonso R; Geisler JG; Duan W
    Exp Neurol; 2017 Jul; 293():83-90. PubMed ID: 28359739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.
    Moffitt H; McPhail GD; Woodman B; Hobbs C; Bates GP
    PLoS One; 2009 Nov; 4(11):e8025. PubMed ID: 19956633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The p75 neurotrophin receptor augments survival signaling in the striatum of pre-symptomatic Q175(WT/HD) mice.
    Wehner AB; Milen AM; Albin RL; Pierchala BA
    Neuroscience; 2016 Jun; 324():297-306. PubMed ID: 26947127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease.
    Zhao X; Chen XQ; Han E; Hu Y; Paik P; Ding Z; Overman J; Lau AL; Shahmoradian SH; Chiu W; Thompson LM; Wu C; Mobley WC
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5655-64. PubMed ID: 27601642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
    Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
    Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.